BioDlink Unveils Major Advances in Biologics Development Between Europe and China

In a commendable showcase at Biologics CDMO Europe 2025, BioDlink, a prominent player in the contract development and manufacturing of biologics, highlighted its significant contributions to the industry. At this esteemed event, the company revealed its crucial role in the approval and manufacturing of the world’s pioneering EGFR-targeted antibody-drug conjugate (ADC) aimed at treating recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

Keynote Insights from Dr. Jian Zhang

Dr. Jian Zhang, the Chief Operating Officer at BioDlink, addressed the audience with his keynote presentation themed "Linking Europe and China — Mutual Success in Biologics CMC Development." During his speech, he elaborated on the global and Chinese biologics market trends, noting that as of 2025, China accounted for an impressive 54% of ADCs and 48% of both bispecific and tri-specific antibodies in global Phase I/II trials. Furthermore, he revealed that in the first three quarters of 2025 alone, the total licensing deal value emanating from China soared to $920.3 billion, marking a staggering rise of 77% compared to the previous year, and included 16 deals valued at over a billion dollars each.

Innovative Project Execution

Dr. Zhang showcased BioDlink's exceptional capabilities in executing cross-regional projects. He provided case studies illustrating how the company’s integrated, end-to-end Chemistry, Manufacturing, and Controls (CMC) platform has enabled seamless technology transfers, agile regulatory compliance, and accelerated manufacturing timelines. Notably, BioDlink recently introduced a groundbreaking Becotatug Vedotin injection, which gained marketing approval from China's National Medical Products Administration (NMPA). This injection marks a historic milestone as the first EGFR-targeted ADC approved globally, signifying a transformative therapeutic advancement for R/M NPC.

Award-Winning Leadership

In a remarkable testament to its industry leadership, BioDlink was honored with the title of Biologics CDMO of the Year during the Biologics CDMO Excellence Europe 2025 awards. This accolade acknowledged the company’s excellence across crucial customer needs, such as quality, speed, and cost efficiency.

Engaging Industry Leaders

At the event, BioDlink sponsored a forum titled “Tech-Transfer Simplified Lessons across the Lifecycle.” Dr. Zhang actively participated in discussions alongside leading CEOs, multinational corporation executives, and prominent leaders in research and investment. He emphasized that technology transfer should be perceived not merely as a technical process but as a strategic transition phase integral to ensuring quality, efficiency, and favorable commercial outcomes. The dialogue underscored the necessity for seamless technology transfer to further propel China's status as a global innovation hub, fostering greater speed, an expansion of modalities, and a shift toward NewCo and out-licensing financing.

Commitment to Innovation

Dr. Zhang concluded, “We are empowering our global clients to innovate more fearlessly. With our world-class facilities anchored in Asia and strategic connections within Europe, BioDlink serves as a key bridge to China's rapidly evolving drug discovery and CMC development landscape, offering significant advantages in speed and cost. We are committed to acting as a strategic CDMO partner for global pharmaceutical entities in their endeavors to develop first-in-class and advanced therapies.”

About BioDlink

BioDlink Biopharm Co., Ltd. (Stock Code: 1875.HK) stands as a leading global contract development and manufacturing organization (CDMO), with a specialization in biologics and bioconjugates like ADCs/XDCs. Headquartered in Suzhou, the company boasts centers in Shanghai and Beijing and provides comprehensive, end-to-end services that span from early research and development (RD) to full-scale commercial manufacturing.

Employing a one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for precise conjugation—BioDlink aids in accelerating development timelines, enhancing efficiency, and driving down costs.

With four commercial manufacturing lines capable of large-scale sterile fill-finish processes and a globally recognized GMP-aligned quality system, the company has earned accreditation from PMDA in Japan and facilitated product approvals across numerous international markets, including China, Indonesia, Nigeria, Pakistan, Colombia, and Bolivia. Guided by the ethos of "Quality First, Innovation Driven, Success Together," BioDlink is dedicated to enhancing global access to next-generation biologics while fostering trustworthy partnerships around the world.

For additional information, visit BioDlink's official website.